Bio-Techne

Bio-Techne and its subsidiaries develop, manufacture and sell biotechnology reagents and instruments for the research and clinical diagnostic markets. The company operates with three reporting segments: Biotechnology, which provides consumables used for conducting laboratory experiments including proteins, antibodies, immunoassays, flow cytometry products, intracellular signaling products, and biologically active chemical compounds; Protein Platforms, which develops and commercializes proprietary systems and consumables for protein analysis; and Diagnostics, which provides a range of controls and calibrators used with diagnostic equipment and as proficiency testing tools.
  • TickerTECH
  • ISINUS09073M1045
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

An unfavourable environment weighs on BIO-TECHNE CORP., which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of BIO-TECHNE CORP. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date September 3, 2019, the closing price was USD 185.65 and its target price was estimated at USD 170.97.

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

An unfavourable environment weighs on BIO-TECHNE CORP., which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of BIO-TECHNE CORP. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date September 3, 2019, the closing price was USD 185.65 and its target price was estimated at USD 170.97.

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ResearchPool Subscriptions

Get the most out of your insights

Get in touch